Zeiss Mite Q1 sales fell short of expectations, withdraws guidance; stock price declines

LootboxPhobia · 2026-02-12T15:15:40+00:00

Zeiss Meit’s first-quarter sales and organic growth both fell short of expectations, with adjusted EBITDA 60% below forecasts. The company has withdrawn its guidance for fiscal year 2026 and plans to update its strategic plan in April. The ophthalmic equipment and microsurgery divisions also underperformed, with order volume declining by 9.7%.

LootboxPhobia

2026-02-12 15:15:40

Abstract generation in progress

Investing.com – Carl Zeiss Meditec reported first-quarter sales on Thursday that fell short of market expectations by 2%, with organic growth also below expectations at -2.1%, compared to an anticipated +1.2%.

The company’s adjusted EBIT (Earnings Before Interest and Taxes) was 10 million euros, 60% below expectations of 25.6 million euros, with market consensus at that level.

As announced in January this year, Zeiss Meditec has withdrawn its guidance for fiscal year 2026. The company is currently reviewing its outlook and plans to publish a broader strategic plan by the latest during its mid-year earnings update in April.

The ophthalmic equipment division reported organic growth of -2.4%, versus market expectations of flat growth, with EBIT falling 154% short of expectations, resulting in a profit margin of -2.3%, compared to an expected 4.1%.

The microsurgery division also underperformed, with organic growth of -0.9% versus a market consensus of +5.0%, EBIT falling 30% short of expectations, with a profit margin of 8.4% versus an expected 11.3%.

Order volume declined by 9.7%, but this is compared to the same period last year, which saw a 21.4% increase after adjusting for exchange rates and acquisitions.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.